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ABSTRACT Amyloid fibrils are self-assembled protein homopolymers that play 
central roles in the pathology of several human diseases, most notably in progressive 
neurodegenerative diseases such as Alzheimer’s disease (AD). In AD, fibrils are 
formed by the amyloid-β (Aβ) peptide, an enzymatic cleavage product that is naturally 
produced in human brain tissue. The fibrillar Aβ accumulates in deposits known as 
senile plaques in the diseased AD brain, and the processes by which this occurs are 
postulated to be primary causes of the neuronal loss that is associated with AD 
progression. As such, it is of great importance to understand how Aβ fibrils are 
formed, and why they exert neurotoxic effects in AD patients. 
 
In pursuit of this goal, there is a need for more effective and precise methods of 
analysing amyloid material. In this work, the aim was to improve the read outs of 
techniques that are currently used, and to develop novel methods for amyloid 
detection. The main focus has been on small molecules that work as light-switch 
molecules in presence of amyloids, i.e. they exhibit greatly enhanced fluorescence 
intensity upon binding to amyloid fibrils. I have characterised the classic amyloid stain 
thioflavin-T (ThT), and showed how it can differentiate between different amyloid 
samples based on their morphological attributes, particularly upon detection of its 
fluorescence lifetime. I have also characterised the binding and fluorescent properties 
of YOYO-1; a traditional DNA stain that proved to be an attractive alternative to ThT 
and that therefore may function as a novel amyloid stain, extending the amyloid 
recognition toolbox.   
 
The Thesis also outlines the development of an existing protocol for expression and 
purification of monomeric seed-free amyloid-β(1-42) that has been setup in our 
laboratory in order to facilitate reproducible investigation into the formation kinetics 
of Aβ(1-42) fibrils. 
 
This work is a stepping stone towards studies of amyloid-β formation kinetics and 
neurotoxicity. I intend to utilise the fluorescence techniques described herein, together 
with the developed protocol for Aβ production, to explore different stages of Aβ 
aggregation; how they exert their neurotoxic effects, and if these properties are 
modulated by lipid membranes and molecular crowding effects. 
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Introduction 
“The first symptom the 51-year old woman showed was the idea that she 
was jealous of her husband. Soon she developed a rapid loss of memory. She 
was disoriented in her home, carried things from one place to another and 
hid them, sometimes she thought somebody was trying to kill her and 
started to cry loudly. In the institution her behaviour showed all signs of 
complete helplessness. She is completely disoriented in time and space. 
Sometimes she says that she does not understand anything and that 
everything is strange to her. Sometimes she greets the attending physician 
like company and asks to be excused for not having completed the household 
chores, sometimes she protests loudly that he intends to cut her, or she 
rebukes him vehemently with expressions which imply that she suspects 
him of dishonourable intentions. Then again she is completely delirious, 
drags around her bedding, calls her husband and daughter and seems to 
suffer from auditory hallucinations. Often she screamed for many hours.” 
 – Dr. Aloysius ‘Alois’ Alzheimer, Frankfurt, 1901. 
The horror described above details the first documented case of the neurodegenerative 
disorder that we today know as Alzheimer’s disease (AD), after its German discoverer Alois 
Alzheimer [1]. A pathophysiological hallmark of this disease is the accumulation of 
proteinaceous plaques in the brain [2]. In 1984 a short 4 kDa peptide was recovered from brain 
plaques of AD patients; the amyloid-β peptide (Aβ) [3,4]. It is today well established that 
aggregation of the Aβ peptide into amyloid fibrils [5-7], along with aggregation of another 
protein, tau [8], are key events in the pathogenesis of AD. For the last 30 years, intensive effort 
has been committed into detailing the physico-chemical and biological behaviour of the Aβ 
peptide, in order to (better) understand the origins of this devastating and increasingly 
prevalent disease, and to aid in the development of effective treatments. This thesis describes 
the study of Aβ fibrils, how they form, and how they interact with two fluorescent dyes, 
thioflavin-T and YOYO-1. Thioflavin-T is a classical amyloid stain; we have characterised its 
ability to distinguish between amyloid species. YOYO-1 is a DNA stain, which we have 
characterised for use as an amyloid stain. Better understanding of how amyloid fibrils interact 
with fluorescent dyes not only enables more efficient use of fluorescence-based techniques for 
studies of amyloid fibrils, but can also give us structural insight on amyloid fibrils, and how 
they relate to the aetiology of Alzheimer’s disease. 
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Alzheimer’s disease 
In a report from the WHO Global Burden of Disease it was estimated that dementia contributes 
to 11.2% of years lived with disability in people aged 60 or older. This is more than e.g. stroke 
(9.5%), musculoskeletal disorders (8.9%), cardiovascular disease (5.0%) and cancer (2.4%) [9]. 
By far the most prevalent form of dementia is Alzheimer’s disease (AD), accounting for at least 
50-60% of all cases worldwide. AD is therefore becoming a major healthcare problem; in 2001 
approximately 24 million people suffered from AD, and that figure is expected to rise to 
roughly 80 million by 2040 as a consequence of our (anticipated) increased life expectancies 
[10]. Not only is AD a strongly debilitating disease that causes tremendous suffering for 
patients and their care-givers, but it is also a very costly disease in economic terms, that 
threatens to put an unbearable burden on our current health care systems. As an example, in 
2005 it was estimated that 224,000 of the total 461,000 people with cognitive impairment in the 
UK reside in institutions at an estimated cost of 8.2 billion US dollars, equivalent to 0.6% of the 
UK GDP [11]. To this is to be added the substantial cost of residential and family care-givers, 
in the US in 1998 amounting to 18 billion dollars, mostly due to reduced working hours and 
psychological strain [12]. It hardly needs to be stressed that solving the problem that is 
Alzheimer’s disease is not only a question of human well-being, but also of large societal 
interest. 
AD is at the present day an incurable disease with an invariably fatal outcome. The treatments 
that do exist offers symptomatic relief, and consists of deploying acetylcholine esterase 
inhibitors and/or NMDA-receptor antagonists, in order to assist neurotransmission in the 
degrading brain. Different strategies are employed in the quest for novel disease-modifying 
treatments, e.g. β- and γ-secretase inhibition [13], Aβ immunotherapy [14], and fibril 
formation modulation [15]. There are also epidemiological studies aiming to find parameters 
that affect the prevalence of AD. Use of cholesterol-modulating drugs [16], anti-inflammatory 
drugs [17] and antioxidant intake [18], have all indicated a reduced prevalence of AD. When 
investigated in proper clinical trials these beneficial effects have, however, been hard to verify.   
Part of the incurability problem of AD arises from the lack of efficient diagnostic tools. AD 
diagnosis today is mostly based on behavioural and psychological testing, presence of AD 
biomarkers, and brain imaging such as computer tomography (CT) or magnetic resonance 
imaging (MRI), all of which are non-definitive methods. The definitive confirmation of an AD 
diagnosis is only possible through post-mortem neuropathological examination. This means 
that any putative effective treatment is also dependent on the development of better diagnostic 
tools, in order to administer treatment before the disease has progressed too far. 
The molecular pathology of AD 
AD is characterised by progressive loss of neuronal function leading to memory impairment, 
cognitive decline and orientational disability [15]. A main pathological characteristic of AD is 
the emergence of so-called senile plaques, consisting of insoluble deposits of aggregated 
protein in the medial temporal lobe and cortical areas of the brain [15]. The major 
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proteinaceous content of the plaques was determined when a short peptide was purified from 
brain extracts of AD patients in 1984 by Glenner et al [3]. This peptide was named amyloid-β 
(Aβ), and in 1991 the amyloid hypothesis was formulated [5-7], in which it was postulated that 
aggregation of Aβ into fibrillar plaques initiates a series of events that lead to neuronal loss 
and cognitive decline in AD. AD is also associated with the aggregation of an intracellular 
protein; the microtubule-associated protein tau, which upon hyperphosphorylation forms so-
called neuritic tangles – intracellular protein inclusions that are also typically present in post-
mortem tissue samples of human AD brains [8]. It is still debated whether Aβ or tau is the 
most promising target for a potential treatment, however, the community is relatively unified 
in concluding that both proteins are of great importance for a full understanding of the 
pathology of AD. Recent modelling using in vitro neuronal networks has, however, provided 
experimental evidence for that Aβ pathology precedes and drives the formation of intra-
neuronal tau aggregation [19]. 
The amyloid-β peptide – production and amyloid formation 
The Aβ peptide was found to originate from a larger previously unknown membrane protein, 
which was given the name Amyloid Precursor Protein (APP) [20]. APP is ubiquitously 
expressed in many tissues, but is abundant in neuronal synapses. Its biological function is not 
known, though it has been speculated that APP is involved in ion transport [21] and synapse 
formation [22]. APP can be cleaved proteolytically by several enzymes, including the α-, β- 
and γ-secretases. Cleavage of APP by α-secretase results in a non-amyloidogenic fragment, 
whereas cleavage by β- and γ-secretases produces the range of amyloidogenic fragments 
known as Aβ peptides (fig. 1). β-secretase (β-site APP cleaving enzyme 1, BACE-1) is a 
transmembrane enzyme that cleaves APP into two parts, producing the 12 kDa fragment C99. 
This fragment is thereafter cleaved by γ-secretase to produce the actual Aβ peptide. The 
cleavage site for γ-secretase is not well defined, and therefore a number of Aβ isoforms exists, 
differing in length, commonly from 38-43 residues. Aβ peptides are typically named by the 
length of the peptide from N to C-terminus; Aβ(1-40) is the most commonly produced cleavage 
product in the human brain, whereas the second most common variant Aβ(1-42) has been 
found to be the more abundant isoform present in mature plaques [23,24]. 
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Figure 1. Formation of Aβ peptides by enzymatic cleavage of the amyloid precursor protein (APP) by β- and γ-
secretases. 
Aβ was originally thought to be an abnormal product related to cellular stress. However it was 
discovered in 1992 that Aβ is produced continuously under normal metabolic conditions [25], 
meaning that it exists in both diseased and healthy brains. Recent findings indicate that what 
causes the accumulation of Aβ is reduced clearance, in contrast to increased Aβ production 
[26]. It is established that protein homeostasis declines with old age [27], and subsequently, 
the most significant risk factor for developing AD is increasing age [28]. 
Protein folding and misfolding 
Proteins are a class of molecules that form a basis for all living matter on this planet. All life 
forms that are presently identified are sustained by the same basic principle; the genetic code, 
contained within DNA molecules, is transcribed and translated into proteins that execute the 
majority of the functions of a living organism. Proteins are polymeric molecules consisting of 
unbranched chains of amino acids, covalently associated via amide bonds. There are 20 
naturally occurring amino acids, which, through a myriad of combinations form the vast range 
of protein functions that are found in nature. Many of the functions of proteins are dependent 
on them folding into very precise native structures that make them execute specific cellular 
functions. Protein folding is a step-wise ‘trial and error’-process by which the molecule 
progressively reaches a thermodynamically more stable conformation [29]. The process is also 
aided by the presence of chaperones and other molecules that assist proteins in obtaining and 
maintaining their correct fold, in order to preserve their cellular function. Nevertheless, there 
are instances when proteins fail to fold properly or fail to maintain their correct fold. This 
phenomenon, generally referred to as protein misfolding, results in several severe and often 
incurable human diseases that are characterised by accumulation of aggregated protein 
deposits (see Table 1).  
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Table 1. Human diseases associated with build-up of amyloid protein deposits (adapted from [30]). 
Disease Associated protein/peptide 
Neurological amyloid deposit disorders  
Alzheimer’s disease Amyloid-β peptide (Aβ), Tau 
Parkinson’s disease α-synuclein (αS) 
Frontotemporal dementia with Lewy bodies 
(FTLD) 
Tau 
Huntington’s disease Huntingtin with poly-Q expansions 
Spongiform encephalopathy (Creutzfeldt-
Jakob disease) 
Prion proteins 
Amyotrophic lateral sclerosis (ALS) Superoxide dismutase 1 (SOD1), TDP-43 
Non-neurological systemic disorders  
AL amyloidosis Immunoglobulin light chain 
AA amyloidosis Serum amyloid A protein 
Haemodialysis-related amyloidosis β2-microglobulin 
Familial amyloidotic polyneuropathy Transthyretin 
Lysozyme amyloidosis Lysozyme 
Non-neurological localized disorders  
Type II diabetes Islet amyloid polypeptide (IAPP) 
Injection-localized amyloidosis Insulin 
 
Amyloid fibrils and amyloid detection 
Upon misfolding, all of the proteins in Table 1 adopt astonishingly similar β-sheet-rich 
polymeric structures. These were first discovered in 1854, when the German physician 
Rudolph Virchow poured iodine on a brain sample that had an “abnormal macroscopic 
appearance” [31]. The iodine stained the sample deep purple, and Virchow thereby concluded 
that the sample must consist of starch or cellulose (the distinction between the two was unclear 
in the 19th century), naming the newly discovered substance amyloid (Greek, amylon – starch). 
It later turned out that what Virchow discovered was neither cellulose nor starch, but 
misfolded proteins that had aggregated into what we now call amyloid fibrils. There is 
growing evidence that the ability to form amyloid fibrils is common to all polypeptide chains 
[30,32]; indeed it has even been found that peptides consisting of just a couple of amino acids 
can assemble into fibrils [33]. This generality is likely due to that amyloid fibrils are primarily 
stabilized by hydrogen bonding interactions involving the peptide backbone, and thus of a 
chemical structure that is invariant of the amino acid sequence [34]. Despite this, the tendency 
of a protein to actually form amyloid fibrils correlates strongly with its primary sequence, with 
high hydrophobic side chain-content and/or inherently disordered structures commonly 
resulting in a stronger tendency towards amyloid formation [35,36]. Even though naturally 
occurring amyloid forming proteins differ greatly in primary sequence, the formed fibrils do 
share a surprising amount of biophysical and structural properties.  
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Amyloid fibril structure 
Atomic resolution structural information of amyloid fibrils is hard to obtain due to the size, 
insolubility, and heterogeneity of amyloid assemblies, which complicates the use of traditional 
structural biology methods such as NMR spectroscopy and X-ray crystallography. Instead 
combinatorial approaches involving several time-consuming experimental methods are foten 
required to achieve high-resolution structures [37]. Amyloid fibrils exhibit a characteristic 
diffraction pattern when placed in an X-ray beam, reminiscent of a cross [38], which gives rise 
to the name of the structural feature that makes up the core of the amyloid fibril; a cross-β fold. 
It consists of two or more β-strands that form a highly stable antiparallel or parallel β-sheet 
motif (fig. 2). Therefore, secondary structure determination methods such as circular 
dichroism spectroscopy reveal that amyloid fibrils are strongly dominated by β-sheets, and it 
has been shown by linear dichroism spectroscopy [39] and polarized fluorescence microscopy 
[40] that the β-sheets  of the cross-β core are aligned perpendicularly to the long axis of the 
fibril. Quaternary association of these β-sheet-rich monomers through stacking leads to the 
formation of long extended fibrillar assemblies. The two reflections in the diffraction pattern 
are located at approximately 10 Å and 4.7 Å, corresponding to two characteristic spacings 
between β-sheets in the amyloid fibril (fig. 2); The 10 Å reflection corresponds to the 
interstrand spacing; the distance between the two β-sheets that make up each individual 
monomer. The second is the stacking distance between each set of monomers. These structural 
commonalities provide amyloid fibrils with certain common biophysical characteristics, 
despite major differences in the primary sequence of the monomer.  
 
Figure 2. Three-dimensional representation of the secondary and tertiary structure of an amyloid fibril. This 
example shows 5 monomers of an Aβ(1-40) fragment that are associated by hydrogen bonding into a 
protofilament of an amyloid fibril. The drawing shows the two distinctive spacings that are present in the cross-β 
core of all amyloid fibrils; the  10 Å spacing is the distance between the two sheets in the β-hairpin of each 
individual monomer, whereas the 4.7 Å spacing is the distance between two neighbouring monomers in the fibril 
stack. Image retrieved from the Protein Data Bank, published in Luhrs et. al [41] PDBID: 2BEG. 
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Amyloid fibril detection 
As a consequence of the structural similarity between different amyloid fibrils, it is possible to 
detect them using various general amyloid-binding molecules. Traditionally, the hallmark of 
amyloid detection has been the observation of apple-green birefringence upon staining with 
Congo red (CR) [42]. A more straightforward, and today more common method is the use of 
thioflavin-T (ThT) fluorescence. ThT is a dye that is nearly non-fluorescent in water, but 
exhibits up to a 1000-fold increase in quantum yield upon binding to different amyloid fibrils 
[43]. Both CR and ThT were established as amyloid stains well before their general structural 
features were established; therefore the mechanisms of binding are not fully characterised. 
With atomic-level structure determination being very time-consuming, fluorescence-based 
techniques are essential in studies of amyloid fibrils, as they provide a quick and reliable way 
of evaluating the presence and state of amyloid fibrils. Fluorescence is especially useful in 
experiments dealing with the kinetics of amyloid fibril formation, as emission from amyloid-
binding dyes has proven to be a very successful technique for reproducible measurement of 
the formation of amyloid fibrils. 
 
Figure 3. Schematic illustration of the kinetics of amyloid fibril growth. Early on in the lag phase, the reaction is 
dominated by nucleation events and the fibril mass grows very slowly. As more and more oligomeric seeds are 
formed, fibrils start growing, and secondary nucleation processes occur, thereby dramatically increasing the 
fibril growth rate. When the monomer is depleted the reaction has reached a stationary phase, where most of the 
material is gathered in mature amyloid fibrils that are typically laterally associated to each other. 
 
Kinetics of amyloid growth 
The abundance of mature amyloid plaques in AD brains does not correlate with neuronal loss 
[44]. Instead, attention has shifted towards different small oligomeric amyloid species that are 
only transiently formed during the amyloid formation reaction [45,46]. This highlights the 
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need for a detailed understanding of how and why amyloid fibrils form in real-time. The 
principles governing the kinetics of amyloid-β aggregation in vitro are becoming increasingly 
well understood. Amyloid formation is a nucleation dependent polymerisation process that is 
initiated by a primary nucleation step. However, the progression of amyloid formation has 
been shown to involve different modes of secondary nucleation (i.e. nucleation events 
involving already formed fibrils) and fragmentation, resulting in the appearance of sigmoidal 
growth kinetics when the change in fibril mass is plotted against time (fig. 3). There are several 
mathematical models that describe the microscopic series of events underlying the rates of 
formation of amyloid fibrils [47-50]. In a very elaborate theory of amyloid fibril growth, 
Knowles et. al [48], divides the growth modes of amyloid fibrils into three separate categories; 
nucleation and fragmentation events, growth processes, and dissociation processes (fig. 4). 
Nucleation and fragmentation events lead to the formation of new aggregates. Primary 
nucleation (formation of oligomers from monomers) results in elongation-competent seeds 
that initiate fibril growth reactions; these events typically dominate the distinct lag phase that 
is seen in all amyloid formation reactions where the starting material is monomeric and free 
of pre-formed seeds (fig 3). Primary nucleation on its own is, however, not enough to explain 
the rapid growth of amyloid fibrils that occurs once a critical mass of nuclei have formed. In 
order to explain this kinetic behaviour, fragmentation and secondary nucleation are 
introduced as further processes by which more nuclei are formed [51]. Fragmentation occurs 
when a formed fibril is cleaved into two or more shorter pieces, and acts to enhance amyloid 
formation rates by exponentially increasing the number of free ends in the sample. This 
phenomenon can be observed by vigorously shaking a solution of amyloidogenic protein, 
causing mechanic breaking of existing fibrils, whereupon an increase in the fibril formation 
rate is observed [52]. Secondary nucleation is a process by which already formed fibrils 
catalyse the formation of new oligomers, probably by means of surface interactions. The great 
importance of secondary nucleation has only been discovered recently, and as such, the exact 
mechanisms of how this catalysis occurs are yet not known [51]. 
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Figure 4. Scheme detailing the different processes contributing to the growth of amyloid fibrils. 
 
Growth processes elongate fibrils by addition of monomers to the ends of the growing fibril. 
Kinetic studies have revealed that this process has a first-order concentration dependence on 
both fibril and monomer concentration. This highlights that the growth of amyloid fibrils 
occurs through monomer addition only, and not oligomer addition, which would cause a non-
linear dependence on the monomer concentration [53]. At high concentrations, the structural 
reorganisation upon monomer addition becomes rate-limiting, and the overall growth rate 
becomes zero-order dependent on the monomer concentration. Dissociation processes are 
typically much slower than growth processes in amyloid formation, and as such, they only 
play a major role once the monomer pool is nearly depleted by the end of the reaction [54].  
Amyloid-β fibril structure and polymorphism 
The two most common isoforms of Aβ, the 40-residue and 42-residue length peptides, have 
been extensively studied in order to reveal both their monomeric and their fibrillar molecular 
structures. Still, it is not clear why the 42-residue peptide is more neurotoxic to nerve cells than 
its 40-residue counterpart. One reason for this is that consensus structures have been difficult 
to assemble due to both peptides exhibiting considerable structural polymorphism in their 
amyloid states. Different Aβ preparation methods and different synthesis methods can lead to 
very different structures [55]. This is generally thought to be an effect that also occurs in vivo, 
which further complicates the search for a distinct disease-causing species of Aβ fibrils. On a 
general level, all fibrillar species and most small species are predominantly composed of β-
sheets. A mature fibril consists of one or several protofilaments. Most models describe a two-
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fold symmetry between protofilaments, where the fibril core consists of two filaments laterally 
associated to each other. There are, however, other models suggesting e.g. a three-fold 
symmetry with three filaments associating in a triangular shape to make up the fibril core 
[56,57].  
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Methodology 
Absorption and fluorescence 
One early observation of the physical process we now know as fluorescence was when Sir John 
Fredrich William Herschel in 1846 let sunlight shine on a solution of quinine, and observed a 
“beautiful celestial blue colour”. While Herschel could not explain this spectacular phenomenon 
in the mid-19th century, we now have an extensive understanding of fluorescence [58]. To 
understand fluorescence, we need first to consider the absorption of light by molecules.  
 
Figure 5. Jablonski energy diagram describing the physical processes involved in absorption, fluorescence and 
phosphorescence. 
 
Any atom or molecule can be described in terms of an energy diagram (fig. 5). The energy 
diagram contains a representation of the different energetic states in which the molecule can 
exist, where the lowest energy state is called the ground state (S0), and any state higher in 
energy is called an excited state (S1, S2, etc.). If the molecule interacts with a photon that 
energetically matches an energy gap between two states, the molecule has a probability of 
absorbing the energy of the photon, thereby transitioning into the higher state. This is called 
the Bohr frequency condition, and is a direct consequence of the Planck-Einstein relation (eq. 
1) which relates photon energy (E) to its frequency (ν) or wavelength (λ), and where h is 
Planck’s constant, and c is the speed of light.  
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𝐸 = ℎ𝜈 =
ℎ𝑐
𝜆
                                                                     (1) 
This process by which photon energy is transferred to molecules is called absorption, or in the 
context of fluorescence, excitation. A molecule which has absorbed energy and transitioned 
into a higher energetic state is called an excited molecule. As nature strives for energy 
minimisation, an excited state is usually relaxed back down to the ground state very rapidly. 
This can occur through a number of different processes, the ones most relevant to this work 
are listed in figure 5. 
Fluorescence is the process when relaxation occurs through the release of a photon. The 
emitted photon is usually lower in energy than the absorbed photon. This is called the Stokes’ 
shift, and happens because the molecule rearranges itself internally before the emission event 
happens; therefore some of the some excitation energy is released as heat, and the emitted 
photon has lower energy than the absorbed photon. Sometimes a molecule transitions into 
what is called a triplet state through a process known as intersystem crossing. Relaxation from 
the triplet state is a forbidden transition, and therefore, emission from this state is very long-
lived, and goes by a specific name, phosphorescence. 
Absorption and fluorescence spectroscopy 
In absorption spectroscopy, a sample can typically be irradiated with light of a fixed frequency. 
The intensity of light that passes through the sample (I) is then detected and compared to the 
initial light intensity (I0) (eq. 2), in order to determine the amount of light that was absorbed 
by the sample. The logarithm of this value is the absorptivity (A). 
𝐴 = 𝑙𝑜𝑔
𝐼
𝐼0
                                                             (2) 
Measuring the absorptivity over a range of wavelengths gives an absorbance spectrum, which 
is the absorptivity of the sample, plotted against the wavelength of absorbed light. Figure 6 
shows the absorbance spectrum of rhodamine-6G (R6G), a commonly used fluorescent dye. 
The absorbance spectrum shows that R6G absorbs visible light in a wavelength region between 
~450 nm and 575 nm, with the absorbance maximum being 530 nm. 
 13 
 
 
Figure 6. Absorption spectrum of rhodamine-6G in water. Data retrieved from 
https://www.thermofisher.com/se/en/home/life-science/cell-analysis/labeling-chemistry/fluorescence-
spectraviewer.html 
 
Steady-state fluorescence spectroscopy is similar to absorption spectroscopy. The sample is 
irradiated by a wavelength of light that is absorbed by the molecule of interest, typically at or 
near the absorption maximum, to achieve maximum efficiency. Instead of detecting the 
amount of light that that is absorbed by the sample, one measures the amount of photons that 
are emitted through fluorescence. This is done by exciting the sample with light of a fixed 
wavelength, and then measuring the amount of photons emitted at another wavelength. The 
plot of emission intensity versus the wavelength of emission is called an emission spectrum, 
and describes the relative intensity of fluorescence emission of a molecule. Continuing with 
the example of R6G, we observe that this molecule emits light in a range between 500 and 700 
nm, with an intensity peak at 566 nm (fig 7, red curve). Similarly, one can record the excitation 
spectrum; emitted photons are then detected at a fixed wavelength, and different excitation 
wavelengths are scanned to produce a record of the excitation intensity. An excitation 
spectrum thereby describes the absorption spectrum of only the emitting species. In the case 
of R6G, we find that the optimal excitation is 530 nm, which is the same wavelength as the 
absorption maximum. 
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Figure 7. Excitation (red) and emission (blue) spectra of Rhodamine-6G in water. The Stoke’s shift is given by 
the separation of the two peaks. Data retrieved from https://www.thermofisher.com/se/en/home/life-science/cell-
analysis/labeling-chemistry/fluorescence-spectraviewer.html 
 
In many experimental techniques where fluorescence is used as a means of detection, one is 
mainly concerned with the intensity of fluorescence emission and not with the time-scales on 
which the emission processes occur. However, it can prove useful to measure the time-
dependence of fluorescence emission by time-resolved fluorescence spectroscopy, a method that 
detects the time that passes between the excitation event and the emission event. This time, 
which is called the lifetime of fluorescence (τ), is an intensive property that is specific for any 
given fluorophore in a given set of conditions, and it is typically affected by e.g. the chemical 
environment of the fluorophore. Fluorescence emission is a random event, meaning that for 
an ensemble of excited molecules, the time spent in the excited state will be a distribution of 
times corresponding to an exponential decay function (eq. 3), which describes the time-
dependent decay of the emission intensity. If the intensity decay function is multi-exponential 
(i > 1), the fluorophore has several distinct fluorescence lifetimes.  
𝐼(𝑡) = ∑ 𝛼𝑖𝑒
−𝑡/𝜏𝑖𝑛
𝑖=1                                           (3) 
One method of determining the fluorescence lifetime is by time-correlated single photon 
counting (TCSPC). In principle, the time between excitation and emission is measured for a 
high number of emission events using a high-frequency pulsed light source (typically a laser). 
These times are then collected into a histogram describing the time-resolved decay of the 
molecule’s excited state. Using non-linear regression, this decay can be fitted to a multi-
exponential function (eq. 3) and we can extract the fluorescence lifetime(s) (τ) of the molecule. 
The lifetime of the excited state typically changes depending on factors such as the physico-
chemical environment of the fluorophore. It is therefore possible to draw conclusions about 
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e.g. different binding sites by measuring the time-resolved fluorescence of a bound dye. An 
inherent advantage of fluorescence lifetimes is that they are concentration-independent, 
whereas the steady-state emission intensity is dependent on e.g. the concentration of the 
fluorescent molecule. 
Fluorescent molecules and molecular rotors 
Molecules that relax their excited state energy through fluorescence emission are called 
fluorophores. Proteins themselves often contain or are associated with intrinsic fluorophores, 
such as the amino acids tryptophan and tyrosine or the protein cofactor NADH. However, 
most fluorophores used in biological experiments are not intrinsic, but extrinsic, meaning that 
they are not a natural part of the system one wants to investigate. Instead they are associated 
to a protein of interest, either by non-covalent interactions, by covalent chemical conjugation, 
or by cloning and recombinant expression of fusion proteins carrying a fluorescent protein 
such as GFP (green fluorescent protein) [59]. A specific class of fluorophores that is of special 
interest in the context of amyloid fibril research are the so-called molecular rotors; they are 
molecules with fluorescence properties that are strongly dependent on their abilities to rotate 
around a chemical bond(s). A molecular rotor is typically nearly non-fluorescent in water 
solutions, where the rotational relaxation of its excited state is very fast. However, in a 
restricted environment where the rotational motion is hindered or reduced, e.g. in a viscous 
solution or bound to a substrate, its emission intensity is increased by several orders of 
magnitude, producing a ‘light-switch’ effect. The work in this Thesis concerns two molecular 
rotors; thioflavin-T and YOYO-1. 
 
Figure 8. Chemical structure of, Top: the amyloid binding dye thioflavin-T (ThT). Bottom: the DNA intercalator 
YOYO-1. 
Thioflavin-T 
Thioflavin-T (ThT) is a benzothiazole dye (fig. 8) that, although it has been known to stain 
amyloid structures since the 1950’s, saw a widespread increase in usage in the early 1990s as 
the amyloid origins of Alzheimer’s disease pathology was proposed. ThT is a molecular rotor; 
upon binding to amyloid fibrils, rotation around the central carbon-carbon bond is restricted, 
and the emission from ThT is increased by up to three orders of magnitude [60]. ThT stains 
almost all kinds of amyloid fibrils, (some repetitive polypeptides excluded, e.g. polyglutamate 
fibrils that occur in Huntington’s disease) suggesting that it must bind to a common structural 
element. Studies using polarized fluorescence microscopy and linear dichroism have provided 
convincing evidence that ThT binds in groove-like channels that are formed by amino acid 
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side-chains protruding from the β-sheets that make up the fibrillar cross-β core [39,40,61]. This 
is further demonstrated by the structural similarity of many amyloid-binding molecules, such 
as thioflavin-T, congo red, chrysamine-G, PTAA, Pittsburgh compound B, and other amyloid-
binding molecules that are all small aromatic molecules with elongated shapes [62]. This type 
of channel-binding is reminiscent of groove-binding in double-stranded DNA, and curiously 
enough, there are also studies showing the binding of ThT to double-stranded DNA [63]. 
YOYO-1 
YOYO-1 is a homodimeric molecule consisting of two monomers of oxazole yellow (YO) 
bound together by an amine linker (fig. 8). It is a molecular rotor, like ThT, and as such, it is 
nearly non-fluorescent in aqueous solution [64]. Traditionally, YOYO-1 is used as a fluorescent 
DNA stain. It binds to double-stranded DNA and intercalates its two chromophores between 
the base-pairs in the DNA stack, leading to restriction of the rotational freedom in the YO 
moieties, and to a dramatic increase in emission [65]. YOYO-1 is widely used due to its low 
background fluorescence, its high extinction coefficient (98,000 M-1cm-1), and its strong binding 
affinity for double-stranded DNA. It belongs to a family of homodimeric cyanine DNA-
binding dyes, all together covering a large portion of the visible spectrum. The elongated 
shape and the molecular rotor nature, together with the favourable spectral properties of 
YOYO-1, sparked our interest into investigating the use of YOYO-1 to study amyloid fibrils.  
Polarized Light Spectroscopy 
Polarized light spectroscopy is a kind of differential absorption spectroscopy where the 
difference in absorption between light of different polarisation is measured. Two kinds of 
polarised light spectroscopy have been used in this work: circular dichroism (CD), and linear 
dichroism (LD). CD is the difference in absorbance of right-handed vs. left-handed polarised 
light in a sample. CD will give information on the presence of chiral centres in the molecule, 
and is a technique that has become particularly useful to study proteins or DNA, both of which 
contain chiral carbon atoms in their backbone structures. In proteins, the chiral carbon atoms 
that make up their peptide backbone give rise to CD spectral shapes that are characteristic to 
different secondary structure elements of proteins (α-helices, β-sheets, etc.), making CD the 
primary tool to estimate protein secondary structure. In the context of amyloid fibrils, CD can 
be used to monitor the β-sheet content of a sample, thereby directly assessing the fibril 
formation as the protein transitions from a statistical coil to a β-sheet rich structure. Figure 9 
shows the change in CD as a solution of Aβ aggregates into amyloid fibrils. Initially, the 
protein is in a statistical coil structure, as indicated by a negative peak at 200 nm (dark colours). 
As the protein aggregates into amyloid fibrils (light colours), the negative peak is shifted 
towards 218 nm, representing formation of β-sheet structures in the sample. 
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Figure 9. Formation of amyloid fibrils by Aβ(1-42) followed by circular dichroism. The formation of β-sheets 
associated with amyloid fibril formation is observed as a relative increase in the negative peak at 218 nm compared 
to the negative peak at 200 nm. 
 
Linear dichroism is a technique similar to CD, but based on linearly polarised light instead of 
circularly polarised light. The probability of absorption is dependent on the angle between the 
electric component of the photon, and the electric dipole moment of the molecule. This means 
that the orientation of a molecule will determine the likelihood of absorption to occur when a 
molecule is irradiated with linearly polarised light. In an LD measurement, the sample is 
irradiated with light polarised parallel and perpendicular to an orientation axis, and the 
difference between these two irradiation modes is measured (eq. 4).  
𝐿𝐷 = 𝐴∥ − 𝐴⊥                                          (4) 
A randomly oriented population of molecules will absorb both these two polarisations to the 
same extent, and the linear dichroism is therefore zero. However, if a sample is in some way 
aligned so that the dipole moments of the absorbing molecules are oriented in relation to the 
orientation axis, the difference in absorption of the two polarisations will be non-zero, thereby 
giving rise to a linear dichroism spectrum. 
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Figure 10. A couette flow cell, with two concentric glass cylinders. In the experimental setup used in this work, 
the outer cylinder is rotating around the dashed rotational axis, and the inner cylinder is fixed. This creates a 
hydrodynamic shear flow between the two cylinders. 
 
In the case of protein polymers, such as amyloid fibrils, one can orient a sample by introducing 
it into a hydrodynamic shear flow. The fibrils will be stretched out in the direction of the flow, 
and thereby be oriented in relation to the orientation axis of the instrument. In this work, this 
is done using a glass Couette flow cell; a rotating glass tube with a fixed glass cylinder on the 
inside (fig. 10). If a solution is introduced between the cylinder and the tube, the solution will 
form a hydrodynamic flow, and molecules above a certain size (related to the shear rate of the 
flow) will become oriented along the radial axis of the flow cell. LD thereby selectively 
measures absorption properties of only oriented molecules, and can therefore be effectively 
used to study binding of small molecules to biopolymers. A typical fluorophore is too small to 
orient in a hydrodynamic flow, but upon binding to an amyloid fibril, it acquires the 
orientation of the amyloid fibril, and therefore produces an LD signal.  
Atomic Force Microscopy 
Atomic force microscopy (AFM) is a scanning-probe microscopy technique that is especially 
sensitive in scanning height differences in the z-direction, making it very well suited for 
studies of e.g. surface structures or molecules immobilized on surfaces. In AFM, a very small 
scanning tip (probe) is attached to the bottom of a flexible cantilever. The cantilever is then 
positioned above the sample and the tip is moved towards the surface. When the tip 
approaches an object, van der Waal’s forces will cause the cantilever to deflect. This deflection 
can then be very precisely detected by aiming a laser at the cantilever and measuring how the 
laser light reflection changes (fig. 11), thereby measuring how the tip reacts to objects directly 
beneath it. Usually a feedback mechanism is employed to ensure that the tip does not make 
actual contact with the surface, but rather hovers above the surface at a constant force, and the 
signal is instead determined by monitoring feedback voltage. This technique is called semi-
contact AFM, as the probe is not in contact with the surface. The lateral resolution of AFM is 
governed by the size of the probe and the precision of the piezo-electric systems that control 
the scanning, both of which can be manufactured to achieve sub-nanometre resolution, several 
orders of magnitude higher than that of a conventional optical microscope. 
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Figure 11. Schematic figure of an AFM microscope illustrating how the cantilever holding the tip is deflected 
upon interaction with the substrate, thereby causing a reflection of the laser beam. 
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Recombinant expression and purification of monomeric 
amyloid-β 
Accurate accounts on the kinetics of amyloid fibril formation can only be obtained with careful 
control of the nature of the starting material. It is therefore necessary to obtain highly 
monomeric solutions as starting material so that the rates of formation under seed free 
conditions may be established. For this purpose, this Thesis describes the adaptation and 
further development of a protocol for expression and purification of highly monomeric seed-
free amyloid-β(1-42). The protocol builds on the method originally described by Walsh and 
Linse [66]. As Aβ(1-42) is sequestered to inclusion bodies in E. coli [66], the purification 
procedure therefore requires purification of inclusion bodies followed by solubilisation in 
order to release the expressed protein. 
Cloning and expression 
Sequence-verified PetSac plasmids containing the Aβ(1-40) and Aβ(1-42) genes (gift from Prof. 
Sara Linse at Lund University) were transformed into an expression strain of E. coli (BL21 DE3) 
by calcium-heat shock and spread on ampicillin (50 mg/ml) LB agar plates. Single colonies 
were picked and inoculated into ampicillin LB (50 mg/ml) and kept as frozen glycerol stocks 
at -80°C. Plasmids were also transfected analogously into E. coli (DH5α) for future plasmid 
preparation and potential cloning experiments. 
For expression of Aβ(1-42), a PetSac plasmid carrying a synthetic gene of the human Aβ(1-42) 
peptide (gift from Prof. Sara Linse, Lund University) was inserted into E. coli (strain BL21 
(DE3) pLysS) and grown on LB agar plates (10 g L-1 tryptone, 5 g L-1 yeast extract, 10 g L-1 NaCl, 
15 g L-1 agar)  containing ampicillin (50 µg/ml) and chloramphenicol (34 µg/ml) overnight. A 
single colony was picked and inoculated into an overnight culture of 10 mL LB medium (10 g 
L-1 tryptone, 5 g L-1 yeast extract, 10 g L-1 NaCl) containing ampicillin (50 µg/ml) and 
chloramphenicol (34 µg/ml). The following day, 750 mL of ZYM-5052 auto-inducing cell 
culture medium (1% tryptone, 1% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM 
NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2X trace metal solution, 0.5% glycerol, 0.05% glucose 
and 0.2% lactose) [67] was inoculated with the pre-culture and incubated at 37° C, 180 rpm 
shaking overnight to induce protein expression. The cells were harvested the morning after by 
centrifugation at 4,500x g for 20 min. The cell pellet was reconstituted in 100 mM Tris-HCl, 10 
mM EDTA, pH 8.0 and frozen at -20° C until further use. 
Purification 
To purify Aβ-containing inclusion bodies, a frozen E. coli pellet was thawed in lukewarm 
water and then sonicated for 3 minutes (2 seconds on, 2 seconds pause) at 70% amplitude using 
a Vibra-cell tip-sonicator (Sonics). The sonicated cells were centrifuged at 22,000x g, 4° C for 
10 minutes to pellet cellular material. The pellet was reconstituted in buffer, discarding the 
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supernatant, and the sonication-centrifugation cycle was repeated. After the final sonication-
centrifugation cycle, the pellet was transferred to a homogeniser for solubilisation  
The purified inclusion bodies were solubilized in 20 mL 8 M urea, 10 mM Tris-HCl, 1 mM 
EDTA, pH 8.0 and thereafter diluted to 2 M urea with buffer. The solution was mixed with 
approximately 5 grams of DEAE anion exchanger (Whatman) and stirred for 30 minutes at 4° 
C. The slurry was filtered onto a filter paper in a Buchner funnel, and then washed with 20 mL 
10 mM Tris-HCl, 1 mM EDTA, pH 8.0, followed by 20 mL 25 mM NaCl in the same buffer. 
Aβ(1-42) was then eluted with 35 mL 125 mM NaCl. The eluted protein was filtered through 
a 30 kDa MWCO centrifugal filter to remove large proteins and cellular material, and the 
protein solution was snap-frozen in liquid nitrogen, freeze-dried in low-binding 
microcentrifuge tubes (Axygen), and kept at -80° C until further use. 
Samples from all steps of the purification procedure were analysed on an SDS-PAGE gel (4-
12% Bis-Tris, Invitrogen) to evaluate Aβ purity and expression level, see (fig. 12). Aβ(1-42) is 
4.5 kDa in size, and appears as a single band in fig. 5, just above the 3.5 kDa band in the protein 
ladder.  
 
Figure 12. SDS-PAGE of samples recovered during Aβ(1-42) work-up. From left to right: (L): Novex Sharp 
Prestained Protein Standard, (S1): First sonication supernatant, as is, and 10x diluted, (S2): Second sonication 
supernatant, as is, and 10x diluted, (U): Flowthrough from urea solubilisation, (W): 10 mM Tris-buffer wash, 
(E25): 25 mM NaCl wash, (E125): 125 mM NaCl elution, (F125): 30K MWCO-filtered 125 mM NaCl elution. A 
~4.5 kDa band corresponding to Aβ(1-42) is visible in all lanes except S1. 
 
Prior to each experiment, a small amount of lyophilized Aβ was reconstituted in 7 M 
guanidium hydrochloride and incubated on ice for 30 min. The solution was then injected onto 
a Superdex 75 GL 10/300 size-exclusion chromatography column, and eluted with the buffer 
that would be used in the subsequent experiments at a flow rate of 0.7 ml/min (fig. 13). 
Fractions were collected as 500 µl aliquots and the two aliquots corresponding to the monomer 
peak, eluting at approximately 15-17 mL were collected and combined. The Aβ concentration 
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of the combined fractions was determined using UV-Vis absorbance spectroscopy, using an 
extinction coefficient of ε280= 1400 M-1cm-1 [66].  
 
Figure 13. Chromatogram showing the purification of monomeric Aβ(1-42) using a Superdex 75 GL 10/300 
size-exclusion column. The peak at ~15 mL corresponds to monomeric Aβ(1-42). The subsequent peaks are buffer 
components, as indicated by the change in conductivity. 
 
Amyloid fibril formation controls 
The quality of the purified Aβ solutions was assessed by examining the reproducibility of 
amyloid formation in a ThT amyloid kinetics assay and by examining the resulting fibrils by 
atomic force microscopy. This was typically done by diluting purified Aβ to 5 µM 
concentration, followed by addition of 1 µM ThT. The samples were distributed as at least 
three replicates in a 96-well microtiter plate, and the ThT fluorescence was read intermittently 
over 8 hours. The resulting kinetic traces replicate very well the known amyloid formation 
kinetics described in the theoretical section of this thesis, and also show that the variance of 
the reaction is low (fig. 14, left). 
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Figure 14. Left: Formation of amyloid fibrils by Aβ(1-42), as measured by ThT fluorescence at different dye-
loads. Typical sigmoidal kinetics with a distinct lag phase, a fast growth phase and a plateau phase. 3 traces of 
the same experiment are shown to give an indication of the reproducibility of the experimental setup. Right: 
AFM imaging of Aβ(1-42) deposited on a glass surface. 
 
Further, the amyloid-β fibrils were examined in an nTegra PRIMA AFM setup (NT-MDT) to 
confirm the macromolecular size and shape of the obtained fibrils (fig. 14, right). Aβ(1-42) 
fibrils are approximately 8-10 nm in height and range up to 10s of microns in length, a result 
that is in agreement with typical numbers for Aβ amyloid fibrils [68]. This confirms the 
establishment of a functioning protocol for expression and purification of highly monomeric 
Aβ protein, and the relevant assays for studying fibril formation kinetics and morphology. 
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Study I – ThT fluorescence as a tool to differentiate between 
amyloid fibrils 
Background 
The fluorescence enhancement of ThT when it interacts with amyloid fibrils is not always 
linearly related to the concentrations of fibrils and dye. For example, different isoforms of the 
same fibril can often give rise to dramatically different emission intensities for samples that 
are at first glance very similar. In the paper ‘Steady-state and time-resolved Thioflavin-T 
fluorescence can report on morphological differences in amyloid fibrils formed by Aβ(1-40) and Aβ(1-
42)’ I have investigated this heterogeneity in order to better understand how ThT functions in 
its capacity as an amyloid fibril probe.  
Aβ(1-40) and Aβ(1-42) produces different ThT emission in 
concentration-matched samples 
In order to make direct quantitative comparisons between fibril samples of different Aβ 
variants, we setup and used a bischinconinic acid assay (BCA) to estimate the protein 
concentration in our various samples. This procedure enabled us to match the fibril 
concentrations in different samples thereby making it possible to directly compare the ThT 
fluorescence intensities recorded. We did this by measuring the monomer concentration in the 
samples prior to and after fibrillisation, and could therefore also determine the typical 
reactions yields in the fibril forming reactions. We found that both Aβ(1-40) and Aβ(1-42) 
aggregated to a 90-95% extent (paper I, fig. S2). 
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Figure 15. (A) ThT steady-state emission intensity measured in presence of Aβ(1-40) or Aβ(1-42) fibrils 
incubated at either quiescent or agitated conditions. (B) Emission and excitation spectra of the same samples as 
in Top. 
 
Using the concentration-matched amyloid-β fibril samples of Aβ(1-40) and Aβ(1-42), we found 
that the emission intensity from ThT is indeed different for different fibril variants but also for 
different conditions by which each fibril type was prepared (quiescent or agitated) (fig 15A). 
In fibrils formed under quiescent conditions, the emission intensity from Aβ(1-40) is 1.7-fold 
stronger than that of Aβ(1-42). This result suggests that there are profound differences in ThT 
fluorescence enhancement by fibrils formed from these two peptides, an important finding, as 
it reveals that variations in ThT emission intensity does not necessarily relate to variations in 
fibril concentration. For fibrils formed under agitated conditions, Aβ(1-40) still shows stronger 
fluorescence enhancement, though the difference is now 1.3-fold. In general, agitation 
decreases the ThT fluorescence intensity, typically because the forces introduced by shaking 
act to increase the fibril fragmentation rate, but here we show (by AFM analysis) that it also 
appears to induce lateral clustering of fibrils.  
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The emission differences are explained by morphological features of 
Aβ fibrils 
In order to investigate if these differences between Aβ(1-40) and Aβ(1-42) could be explained 
by differences in the structure and/or number of the ThT binding site(s) we measured emission 
and excitation spectra (fig 15B). We found no distinct differences in spectral shape indicating 
that the varying intensity cannot be explained by spectral change. We also measured circular 
dichroism spectra (paper I, fig. 3B) of the fibrils and could conclude that there are no dramatic 
differences in the secondary structure content of the Aβ(1-40) and Aβ(1-42) fibrils, at least not 
at a level that could explain the differences in ThT emission intensity. Therefore, to further 
characterise the origin of the intensity difference, time-resolved ThT fluorescence was used to 
determine the average excited state lifetime of ThT in its fibril-bound state. This revealed a 
small but distinctive and reproducible difference in the intensity-averaged fluorescence 
lifetime between the two fibril types. This difference was independent of the aggregation 
conditions, suggesting that it represents an inherent property of the Aβ(1-40) and Aβ(1-42) 
fibrils respectively. Atomic-level structural studies of Aβ fibrils have indeed indicated slightly 
different structures for Aβ(1-40) and Aβ(1-42) fibrils [56], leading us to suggest that the 
different ThT fluorescence lifetimes represent a slight difference in the ThT binding site for the 
two isoforms. 
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Figure 16. (A): Atomic force microscopy images of Aβ(1-40) fibrils (left panels) formed at quiescent and agitated 
conditions, and Aβ(1-42) fibrils (right panels) formed at quiescent and agitated conditions. (B): Histograms 
showing the height distributions of the same samples as in (A). 
 
Finally we recorded AFM images of the fibril samples in order to compare their morphological 
features (fig. 16A). We found from height measurements of individual fibrils that the Aβ(1-40) 
fibrils are thinner than the Aβ(1-42) fibrils, but also that their height distribution is narrower 
(fig. 16B). It is also evident on a qualitative level that Aβ(1-40) fibrils are longer, at least for 
agitated samples, than Aβ(1-42) fibrils. This is expected, given that Aβ(1-42) has a higher rate 
constant for nucleation, leading to formation of more fibrils, but shorter ones. We thus 
concluded that Aβ(1-40) forms longer and slenderer fibrils, that also appear less laterally 
clustered (paper I, fig. S7), and that this morphological difference allows for higher binding 
capacity (more available ThT binding sites) than the shorter more clumped together Aβ(1-42) 
fibrils. 
Further investigation into the Th-T fluorescence lifetime 
In ongoing work I am further characterising the ThT fluorescence lifetime when bound to Aβ 
fibrils, and present results suggesting that it is more complex than at first thought. First, the 
ThT fluorescence lifetime is dependent on the ratio of ThT:fibrils, as a titration of ThT into a 
fibrillar Aβ sample gives a decrease in the intensity-averaged lifetime of ThT (fig 17A). 
Conversely, the same effect is observed when Aβ(1-42) fibrils are titrated into a ThT solution 
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(fig 17B). The quenching of the ThT fluorescence lifetime is not a result of increased 
contribution of free ThT, as the emission from free ThT is too low to make a significant 
contribution in the time window used to record the decay. These results indicate that as the 
binding of ThT to Aβ(1-42) fibrils is increasingly saturated, the fluorescence emission is also 
quenched. I am currently trying to utilise this effect to measure the formation kinetics of Aβ(1-
42). The quenching effect is especially pronounced at low Aβ(1-42) concentrations, indicating 
that time-resolved ThT fluorescence has the capacity of being very sensitive for low fibril 
concentrations, thus making it especially useful for obtaining information in the normally 
unresponsive lag phase. 
 
Figure 17. Fluorescence emission decay curves of: (A) increasing amounts of ThT in presence of 10 µM Aβ(1-
42) fibrils. (B) increasing amounts of Aβ(1-42) fibrils in presence of 10 µM ThT.  
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Study II – YOYO-1 as a novel amyloid fibril fluorescent stain 
Background 
YOYO-1 (fig. 8), a homodimer derivative of oxazole yellow (YO), is a dye that is typically used 
to detect double-stranded DNA. Each individual YO moiety is a molecular rotor whose 
emission intensity is governed by its ability to rotate around the bond that connects its two 
aromatic ring systems [64]. It has previously been shown to interact with amyloid fibrils [69], 
and I wanted to expand on this study and evaluate its use as an amyloid indicator dye. The 
chemical structure of the individual YO moieties in YOYO-1 bears some resemblance to ThT, 
which sparked our initial interest of testing it as an amyloid stain; further as high binding 
affinity is important for molecular probes for amyloid recognition I decided to test the 
homodimer as it may, due to its higher overall charge display stronger binding. YOYO-1 has 
some inherent advantages; it has a three-fold higher extinction coefficient than ThT, it has a 
very high binding affinity to DNA, which I hoped would translate to amyloids, and its spectral 
properties overlap very well with excitation light sources and standard filters used in e.g. 
fluorescence microscopes and plate readers. Furthermore, it belongs to a family of 
homodimeric cyanine dyes that together covers a large part of the visible spectrum, thus 
opening up the possibility of adapting these dyes into a toolbox that would allow for versatile 
colour-tuning of amyloid fluorescence assays. 
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Figure 18. (A): Absorbance (red), emission (cyan) and excitation (blue) spectra of 150 nM YOYO-1 in solution 
(dashed line) and 150 nM YOYO-1 in presence of 5 µM fibrillar Aβ(1-42) (solid line). (B): Linear dichroism 
spectra of 25 µM fibrillar Aβ(1-42) in presence of 500 nM YOYO-1 (blue) and in presence of 500 nM YOYO-1 
and 500 nM ThT (green). The red curve represents the subtraction of the YOYO-1 only LD spectrum (blue) 
from the YOYO-1 + ThT LD spectrum (green).  
Absorption shift and emission increase of YOYO-1 in presence of 
Aβ(1-42) 
To evaluate the usefulness of YOYO-1 as an amyloid stain, I first measured the absorption and 
fluorescence of samples containing YOYO-1 and Aβ(1-42) amyloid fibrils. YOYO-1 has a dual-
peak absorption band at 460-490 nm. These two peaks are shifted in intensity in presence of 
Aβ(1-42) relative to buffer solution (figure 18A, red curves), with the 490 nm peak becoming 
dominant relative to the 460 nm peak in the fibril-bound state. In accordance with previous 
studies in DNA [64], we attribute this to a conformational change of YOYO-1, from a self-
stacking to a non-stacked conformation upon binding to amyloid fibrils. Fluorescence 
measurements revealed that the emission intensity of YOYO-1 is increased as much as 200-
fold in presence of Aβ(1-42) fibrils. To characterise the binding mode of YOYO-1 to Aβ(1-42) 
fibrils, I measured linear dichroism spectra of Aβ(1-42) fibrils in presence of YOYO-1. The LD 
spectrum (fig. 18B) also shows the dual peak at 460-490 nm, with the 490 nm peak dominating, 
providing further confirmation that the absorption shift from 460 nm to 490 nm represents 
binding of YOYO-1 to Aβ(1-42) fibrils. The positive sign of the LD spectrum indicates that 
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YOYO-1 is bound to Aβ(1-42) fibrils with its long axis parallel to the fibril axis, consistent with 
the binding orientation observed for thioflavin-T [39], and poly(3-thiophene acetic acid) 
(PTAA) [70]. Together, these results indicate that YOYO-1, like ThT, binds into groove-like 
‘channels’ that are formed on the face of the amyloid fibrils by repetitions of amino acid side-
chains protruding from the amyloid cross-β core. 
 
Figure 19. A and B: Emission (blue) and excitation (red) spectra of YOYO-1 in presence of (A) Aβ(1-42) fibrils 
or (B) ct-DNA. C and D: Absorbance spectra of increasing amounts of YOYO-1 in presence of (C) Aβ(1-42) 
fibrils or (D) ct-DNA. 
 
Comparison of YOYO-1 amyloid fluorescence to YOYO-1 DNA 
fluorescence 
Next, I compared the emission and absorption of YOYO-1 in presence of amyloid to that of 
YOYO-1 in presence of double-stranded DNA (fig 19). I found that both the excitation and 
emission spectrum are very similar in the two cases (fig 19A and 19B), indicating that the 
physico-chemical environment of amyloid-bound YOYO-1 is similar as in double-stranded 
DNA. The fold-increase of YOYO-1 is higher when bound to DNA [65], which we attribute to 
intercalation. YOYO-1 is known to intercalate in double-stranded DNA, leading to a strongly 
stabilized ring system, whereas the proposed groove-like binding in amyloid fibrils likely 
results in lesser stabilisation. The absorption shift from 460 nm to 490 nm also seems to mimic 
DNA (fig 19C and 19D), with a regrowth of the 460 nm peak at high dye-loads, indicating a 
saturation of the binding. This saturation is not seen for ThT (paper II, fig. 3), indicating that 
the binding affinity for Aβ(1-42) fibrils of YOYO-1 is stronger than that of ThT, possibly a 
reflection of its stronger electrostatic attraction. 
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Figure 20. Amyloid formation by Aβ(1-42) monitored by YOYO-1 and ThT fluorescence. Top rows: Change in 
YOYO-1 fluorescence as a function of time upon Aβ(1-42) aggregation. Kinetic data were recorded in phosphate 
buffers containing (A) 0 mM sodium chloride and (B) 100 mM sodium chloride. The total Aβ(1-42) 
concentration in each sample was 5 µM. The YOYO-1 concentrations are indicated in the figure legends. 
Bottom rows: Comparison of the change in YOYO-1 fluorescence (red curves) and ThT fluorescence (blue 
curves) as function of time upon Aβ(1-42) aggregation. Kinetic data were recorded in phosphate buffers 
containing (C) 0 mM sodium chloride and (D) 100 mM sodium chloride. The total Aβ(1-42) concentration in 
each sample was 5 µM and the dye concentration was 150 nM. 
 
YOYO-1 as a probe for amyloid formation kinetics  
Finally, I examined the use of YOYO-1 as an amyloid indicator in kinetics measurements. I 
found that although YOYO-1 responds to and reports on fibril formation, it has, under some 
experimental conditions, a concentration dependent effect on the amyloid formation rate (fig 
20A), this is not typically seen for ThT (paper II, fig. S5). It also has a rate-increasing effect 
compared to ThT at equimolar concentrations (fig 20C). This rate-increasing effect is, however, 
eliminated by addition of 100 mM NaCl (fig 20B and 20D), probably due to electrostatic 
screening of the strong positive charge (+4) of YOYO-1. The positive charge of YOYO-1 could 
act to attract negatively charged Aβ(1-42) monomers to the forming fibrils, thereby increasing 
both the nucleation and elongation rate. Similar effects have been observed for naturally 
occurring multivalent cations such as spermine and putrescine [71]. 
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Summary and Outlook 
This thesis details the development of laboratory methods, specifically use of fluorescent dyes, 
to produce and characterise amyloid-β fibrils.  
I have shown how ThT fluorescence is a considerably more complex tool than what is 
appreciated in its standard application and my results explain why it is difficult to relate its 
intensity directly to fibril content. However, my work also shows how careful sample 
preparation and carefully chosen experimental setups makes it possible to utilise this effect, 
allowing for differentiation between amyloid fibrils in a way that is related to their 
morphological appearance. There are also promising indications that the time-resolved ThT 
fluorescence can become an important tool to study formation of Aβ fibrils, as the ThT 
fluorescence lifetime is indirectly dependent on the fibril mass, and possibly also on their 
aggregation state. 
Further, I have provided a biophysical characterisation of the amyloid-binding properties of 
YOYO-1, a classic DNA-binding fluorophore. YOYO-1 emission exhibits a 200-fold increase in 
presence of amyloid-β fibrils, coupled with absorbance shifts related to a stacking to non-
stacking conformational change. YOYO-1 also exhibits linear dichroism in presence of 
amyloid-β fibrils, which not only confirms the binding, but also demonstrates that YOYO-1 
binds parallel to the fibril axis, analogously to the classic stain ThT. As YOYO-1 belongs to a 
family of homodimeric cyanine fluorophores, it provides a novel set of amyloid-binding dyes 
that can be used to colour-tune amyloid fluorescence to a large range of the visible spectrum.  
Both of these studies relate to the interaction of small molecules with the amyloid cross-β 
surface. They stand as further proof of the presence of groove-like channels on the surface of 
amyloid fibrils that provide binding sites for elongated molecules such as ThT or YOYO-1. 
Recent studies have shown that the fibril surface is of great importance for fibril elongation 
rates as secondary nucleation processes in amyloid forming reactions appear dependent on 
the fibril surface and hence possibly on the structural motif that encompass the groove-like 
channels. This interesting mechanic of the amyloid forming reaction is especially interesting 
with respect to the ability of such species to transfer and proliferate throughout the AD brain 
[51,72-74]. 
I have also described the setup of a protocol for expression and purification of Aβ(1-42) for 
amyloid formation kinetics experiments. As a result, I have now established a diverse toolbox 
consisting of specialised fluorescence methods in combination with a production system for 
highly monomeric, seed-free Aβ(1-42), enabling studies of how biological components such as 
lipid membranes modulate the formation of amyloid fibrils and such studies are currently 
underway. The results that I have obtained so far indicate that lipid vesicles increase the rate 
of fibril formation, and I hope to utilise the methods developed here to investigate how the 
presence of lipids affects the structure and morphology of amyloid fibrils, and how these 
features relate to their neurotoxic properties.  
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